Australia based Atomo Diagnostics has announced that it has signed a binding agreement with US-based diagnostics specialist Access Bio Inc. that will see Atomo supply its unique, integrated rapid diagnostic test (RDT) devices to Access Bio for use with its rapid test strip for detection of antibodies to COVID-19.

Finished products being commercialised under this agreement include a COVID-19 rapid antibody test for professional use, and a COVID-19 rapid antibody test for self-test use.

Once relevant regulatory authorisations or approvals are obtained, the Products will be launched in the United States, Canada and Mexico, co-branded by both Access Bio and Atomo, with Access Bio as the listed manufacturer.

Access Bio will also have non-exclusive rights to sell the Products in the rest of the world with the exception of Europe, Australia/NZ and South East Asia where Atomo already has contractual arrangements in place.

Under the agreement, Access Bio is obliged to sell a minimum of two million Products by 30 September 2021.